Skip to main content
NCBI home page
Cellular and Molecular Neurobiology logoLink to Cellular and Molecular Neurobiology
. 1995 Oct;15(5):573–595. doi: 10.1007/BF02071318

Molecular neurobiology and pharmacology of the Vasopressin/Oxytocin receptor family

J Peter 1,✉, H Burbach 1, Roger A H Adan 1, Stephen J Lolait 2, Fred W van Leeuwen 3, Eva Mezey 4, Miklos Palkovits 2, Claude Barberis 5
PMCID: PMC11563090  PMID: 8719042

Abstract

1. VP and OT mediate their wealth of effects via 4 receptor subtypes V1a, V1b, V2, and OT receptors.

2. We here review recent insights in the pharmacological properties, structure activity relationships, species differences in ligand specificity, expression patterns, and signal transduction of VP/OT receptor.

3. Furthermore, the existence of additional VP/OT receptor subtypes is discussed.

Key words: vasopressin, oxytocin, G-protien coupled receptors

References

  1. Adan, R. A. H., Leeuwen, F. W., van, Sonnemans, M. A. F., Brouns, M., Hoffman, G., Verbalis, J. G., and Burbach, J. P. H. (1995). The rat oxytocin receptor in brain, pituitary, mammary gland and uterus: partial sequence and immunocytochemical localization.Endocrinology (in press). [DOI] [PubMed]
  2. Antoni, F. A. (1984). Novel ligand specificity of pituitary vasopressin receptors in the rat.Neuroendocrinology39186–188. [DOI] [PubMed] [Google Scholar]
  3. Audigier, S., and Barberis, C. (1985). Pharmacological characterization of two specific binding sites for neurohypophysial hormones in hippocampal synaptic membranes of the rat.EMBO J.41407–1412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bankowski, K., Manning, M., Haldar, J., and Sawyer, W. H. (1978). Design and synthesis of potent antagonists of the vasopressor response to arginine vasopressin,J. Med. Chem.21850–853. [DOI] [PubMed] [Google Scholar]
  5. Barberis, C., Balestre, M. N., Jard, S., Tribollet, E., Arsenijevic, Y., Dreifuss, J. J., Bankowski, K., Manning, M., Chan, W. Y., Schlosser, S. S., Holsboer, F., and Elands, J. (1995). Characterization of a novel linear radio-iodinated antagonist: An excellent radioligand for vasopressin V1a receptors.Neuroendocrinology (in press). [DOI] [PubMed]
  6. Birnbaumer, M., Seibold, A., Gilbert, S., Ishido, M., Barberis, C., Antaramian, A., Brabet, P., and Rosenthal, W. (1992). Molecular cloning of the receptor for human antidiuretic hormone.Nature357333–336. [DOI] [PubMed] [Google Scholar]
  7. Briner, V. A., Tsai, P., Choong, H. L., and Schrier, R. W. (1992). Comparative effects of arginine vasopressin and oxytocin in cell culture systems.Am. J. Physiol.363F222-F227. [DOI] [PubMed] [Google Scholar]
  8. Brinton, R. D., and Brownson, E. A. (1993). Vasopressin-induction of cyclic AMP in cultured hippocampal neurons.Brain Res.71101–105. [DOI] [PubMed] [Google Scholar]
  9. Brinton, R. E., Gehlert, D. R., Wamsley, J. K., Wan, Y. P., and Yamamura, H. I. (1986). Vasopressin metabolite, AVP 4–9, binding sites in brain: Distribution distinct from that of parent peptide.Life Sci.38443. [DOI] [PubMed] [Google Scholar]
  10. Burbach, J. P. H. (1986). Proteolytic conversion of oxytocin, vasopressin and related peptides in the brain. In Ganten, D., and Pfaff, D. (eds.),Current Topics in Neuroendocrinology (Vol. 5), Springer-Verlag, Berlin, p. 55. [Google Scholar]
  11. Burbach, J. P. H., and De Wied, D. (1981). Memory effects and brain proteolysis of neurohypophyseal hormones. In Sclesinger, D. M. (ed.),Neurohypophyseal Peptide Hormones and Other Biologically Active Peptides, Elsevier/North-Holland, Amsterdam, p. 69. [Google Scholar]
  12. Burbach, J. P. H., and Lebouille, J. L. M. (1983). Proteolytic conversion of arginine-vasopressin and oxytocin by brain synaptic membranes. Characterization of formed peptides and mechanism of proteolysis.J. Biol. Chem.2581487. [PubMed] [Google Scholar]
  13. Burbach, J. P. H., Kovács, G. L., De Wied, D., Van Nispen, J. W., and Greven, H. M. (1983a). A major metabolite of arginine-vasopressin in the brain is a highly potent neuropeptide.Science2211310. [DOI] [PubMed] [Google Scholar]
  14. Burbach, J. P. H., Bohus, B., Kovács, G. L., Van Nispen, J. W., Greven, H. M., and De Wied, D. (1983b). Oxytocin is a precursor of potent behaviourally active neuropeptides.Eur. J. Pharmacol.94125. [DOI] [PubMed] [Google Scholar]
  15. Burbach, J. P. H., Kovács, G. L., De Wied, D., Van Nispen, J. W., and Greven, H. M. (1983c). A major metabolite or arginine vasopressin in the brain is a highly potent neuropeptide.Science2211310–1312. [DOI] [PubMed] [Google Scholar]
  16. Burbach, J. P. H., Wang, X. C., ten Haaf, J. A., and De Wied, D. (1984). Substances resembling C-terminal vasopressin fragments are present in the brain but not in the pituitary gland.Brain Res.306384. [DOI] [PubMed] [Google Scholar]
  17. Butlen, D., Guillon, G., Rajerison, R. M., Jard, S., Sawyer, W. H., and Manning, M. (1978). Structural requirements for activation of vasopressin-sensitive adenylate cyclase, hormonebinding and antidiuretic actions: effects of highly potents analogues and competitive inhibitors,Mol. Pharmacol.141006–1017. [PubMed] [Google Scholar]
  18. Cantau, B., Keppens, S., De Wulf, H., and Jard, S. (1980). (3H)-vasopressin binding to isolated rat hepatocytes and liver membranes: Regulation by GTP and relation to glycogen phosphorylase activation,J. Recept. Res.1137–168. [DOI] [PubMed] [Google Scholar]
  19. Chen, X. F., Tang, T., Zhang, J. W., Miao, H. H., Wang, T. X., and Du, Y. C. (1993). ZNC(C)PR affect development changes of P46 phosphorylation in rat hippocampus.Mol. Reprod. Dev.32251–256. [DOI] [PubMed] [Google Scholar]
  20. Chini, B., Mouillac, B., Ala, Y., Balestre, M. N., Trumpp-Kallmeyer, S., Hoflack, J., Elands, J., Hibert, M., Manning, M., Jard, S., and Barberis, C. TYR 115 is the key residue to determine agonist selectivity in the V1a vasopressin receptor.EMBO J. (in press). [DOI] [PMC free article] [PubMed]
  21. Cornett, L. E., and Cate, C. M. (1989). Direct identification of the rat hepatocyte arginine8 vasopressin receptor with a radiolabelled V1-selective antagonist,J. Recept. Res.91–18. [DOI] [PubMed] [Google Scholar]
  22. Dorsa, D. M., Brot, M. D., Shewey, L. M., Meyers, K. M., Szot, P., and Miller, M. A. (1988). Interaction of a vasopressin antagonist with vasopressin receptors in the septum of the rat brain.Synapse2205–211. [DOI] [PubMed] [Google Scholar]
  23. Du, Y. C., Guo, N. N., and Chen, Z. F. (1994). Autoradiographic approach to the developmental study on the binding sites of AVP4–8 in rat hippocampus.Acta Physiol. Sin.46433–437. [PubMed] [Google Scholar]
  24. Durr, J., Hensen, J., and Schrier, R. W. (1992). High specific activity125I- and35S-labelled vasopressin analogues with high affinity for the V1 and V2 vasopressin isoreceptors.J. Biol. Chem.26718453–18458. [PubMed] [Google Scholar]
  25. Elands, J., Barberis, C., and Jard, S. (1988a). [3H]-[Thr4,Gly7]OT: A highly selective ligand for central and peripheral OT receptors.AM. J. Physiol.253E31-E38. [DOI] [PubMed] [Google Scholar]
  26. Elands, J., Barberis, C., Jard, S., Dreifuss, J. J., Bankowski, K., Manning, M., and Sawyer, W. H. (1988b). [125I] labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29]OVT: A selective OT receptor ligand.Eur. J. Pharmacol.147197–207. [DOI] [PubMed] [Google Scholar]
  27. Elands, J., Barberis, C., Jard, S., Lammek, B., Manning, M., Swayer, W. H., and De Kloet, E. R. (1988c). 1251-d(CH2)5 [Tyr(Me)2,Tyr(NH29)]VP: Iodination and binding characteristics of a vasopressin receptor ligand.FEBS Lett.229251–255. [DOI] [PubMed] [Google Scholar]
  28. Fahrenholz, F., Boer, R., Crause, P., Fritzsch, G., and Grzonka, Z. (1984). Interactions of vasopressin agonists and antagonists with membrane receptors.Eur. J. Pharmacol.10047–58. [DOI] [PubMed] [Google Scholar]
  29. Gaillard, R. C., Schoenenberg, P., Favrod-Coune, C. A., Muller, A. F., Marie, J., Bockaert, J., and Jard, S. (1984). Properties of rat anterior pituitary vasopressin receptors: Relation to adenylate cyclase and the effect of corticotropin-releasing factor.Proc. Natl. Acad. Sci. USA812907–2911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Gerstberger, R., and Fahrenholz, F. (1989). Autoradiographic localization of V1 vasopressin binding sites in rat brain and kidney.Eur. J. Pharmacol.167105–116. [DOI] [PubMed] [Google Scholar]
  31. Gorbulev, V., Büchner, H., Akhundova, A., and Fahrenholz, F. (1993). Molecular cloning and functional characterization of V2 (8-lysine) vasopressin and oxytocin receptors from a pig kidney cell line.Eur. J. Biochem.2151–7. [DOI] [PubMed] [Google Scholar]
  32. Granot, Y., Erikson, E., Fridman, H., van Putten, V., Williams, B., Schriers, R. W., and Maller, J. L. (1993). Direct evidence for tyrosine and threonine phosphorylation and activation of mitogenactivated protein kinase by vasopressin in cultured rat vascular smoot muscle cells.J. Biol. Chem.2689564–9569. [PubMed] [Google Scholar]
  33. Gu, B. X., and Du, Y. C. (1991). The neuropeptide ZNC(C)PR can induce c-fos and c-src transcriptions in the hippocampus of newborn rats.Acta Biochem. Biophys. Sin.23537–542. [Google Scholar]
  34. Gu, B. X., and Du, Y. C. (1992). Arginine-vasopressin C-terminal peptide stimulates inositol phospholipid metabolism in rat hippocampus.Chin. J. Biochem. Biophys.23287–294. [Google Scholar]
  35. Guillon, G., Butlen, D., Cantau, B., Barth, T., and Jard, S. (1982). Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: relation to adenylate cyclase activation.Eur. J. Pharmacol.85291–304. [DOI] [PubMed] [Google Scholar]
  36. Guillon, G., Balestre, M. N., Roberts, J. M., and Bottari, S. P. (1987). Oxytocin and vasopressin: distinct receptors in myometrium.J. Clin. Endocrinol. Metabol.641129–1135. [DOI] [PubMed] [Google Scholar]
  37. Howl, J., Parslow, R. A., and Wheatley, M. (1995). Defining the ligand-binding site for vasopressin receptors: A peptide mimetic approach.Biochem. Soc. Trans.23103–108. [DOI] [PubMed] [Google Scholar]
  38. Jard, S., Gaillard, R. C., Guillon, G., Marie, J, Schoenenberg, P., Muller, A. F., Manning, M., and Sawyer, W. H. (1986). Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.Mol. Pharmacol.30171–177. [PubMed] [Google Scholar]
  39. Jard, S., Elands, J., Schmidt, A., and Barberis, C. (1988). Vasopressin and oxytocin receptors: an overview. In Imura, H., and Shizume, K. (eds.),Progress in Endocrinology, Elsevier, Amsterdam, pp. 1183–1188. [Google Scholar]
  40. Jurzak, M. N., Fahrenholz, F., and Gerstberger, R. (1993). Vasopressin anti-idiotypic antibody staining in the rat brain: Colocalization with [35S][pGlu4, Cys6] AVP(4–9) binding sites.J. Neuroendocrinology5523–531. [DOI] [PubMed] [Google Scholar]
  41. Kelly, J. M., Abrahams, J. M., Phillips, P. A., Mendelsohn, F. A. O., Grzonka, Z., and Johnston, C. I. (1989). [125I]-d(CH2)5[Sar7]VP: A selective radioligand for V1 vasopressin receptors,J. Recept. Res.927–41. [DOI] [PubMed] [Google Scholar]
  42. de Keyzer, Y., Auzan, C., Lemne, F., Beldjord, C., Thibonnier, M., Bartagna, X., and Clauser, E. (1994). Cloning and characterization of the human V1b pituitary vasopressin receptor.FEBS Lett.356215–220. [DOI] [PubMed] [Google Scholar]
  43. Kimura, T., Tanizawa, O., Mori, K., Brownstein, M. J., and Okayama, H. (1992). Structure and expression of a human oxytocin receptor.Nature356526–529. [DOI] [PubMed] [Google Scholar]
  44. Kinter, L. B., Huffman, W. F., and Stassen, F. L. (1988). Antagonists of the antidiuretic activity of vasopressin.Am. J. Physiol.254F165-F177. [DOI] [PubMed] [Google Scholar]
  45. Kinter, L. B., Ilson, B. E., Caltabianol, S., Jorkasky, D. K., Murphy, D. J., Solleveld, H. A., Rhodes, G. R., Brooks, D. P., Albrightson-Winslow, C. R., Stote, R. M., and Huffman, W. F. (1991). Antidiuretic hormone antagonism in humans: Are there predictors? In Jard, S., and Jamison, R. (eds.)Vasopressin, John Libbey Eurotext, Paris, pp. 321–329. [Google Scholar]
  46. Kiraly, M., Audigier, S., Tribollet, E., Barberis, C., Dolivo, M., and Dreifuss, J. J. (1986). Biochemical and electrophysiological evidence of functional vasopressin receptors in the rat superior cervical ganglion.Proc. Natl. Acad. Sci. USA835335–5339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. De Kloet, E. R., Voorhuis, Th. A. M., Burbach, J. P. H., and De Wied, D. (1985b). Autoradiographic localization of binding sites for the arginine-vasopressin metabolite AVP (4–9) in rat brain.Neurosci. Lett.567. [DOI] [PubMed] [Google Scholar]
  48. Kojro, E., Eich, P., Gimpl, G., and Fahrenholz, F. (1993). Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor.Biochemistry3213537–13544. [DOI] [PubMed] [Google Scholar]
  49. Kovács, G. L., and De Wied, D. (1994). Peptidergic modulation of learning and memore processes.Pharmacol. Rev.46269–291. [PubMed] [Google Scholar]
  50. van Leeuwen, F. W., Van Der Beek, E. M., Van Heerikhuize, J. J., Wolters, P., Van Der Meulen, G., and Wan, Y. P. (1987). Quantitative light microscopic autoradigraphic localization of binding sites labelled with [3H] vasopressin antagonist d(CH2)5 Tyr(Me)VP in the rat brain, pituitary and kidney.Neuroscience Lett.80121–126. [DOI] [PubMed] [Google Scholar]
  51. Lolait, S. J., O'Carroll, A.-M., McBride, O. W., Konig, M., Morel, A., and Brownstein, M. J. (1992). Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus.Nature357336–339. [DOI] [PubMed] [Google Scholar]
  52. Lolait, S. J., Du, Y.-C., Wu, J.-H., Jiang, X.-M., and Gu, Y.-J. (1994). Characterization of binding sites of a memory-enhancing peptide AVP (4–8) in rat cortical synaptosomal membranes.Peptides151273–1279. [DOI] [PubMed] [Google Scholar]
  53. Lolait, S. J., Mezey, E., Mahan, L. C., Felder, C. C., Button, D., Young, W. S., III, O'Carroll, A.-M., and Brownstein, M. J. (1995).PNAS (in press). [DOI] [PMC free article] [PubMed]
  54. Lutz-Bucher, B., and Koch, B. (1983). Characterization of specific vasopressin receptors for vasopressin in the pituitary gland.Biochem. Biophys. Res. Commun.115492–498. [DOI] [PubMed] [Google Scholar]
  55. Maggi, M., Kassis, S., Malozowski, S., Guardabasso, V., and Rodbard, D. (1986). Identification and characterization of a vasopressin isoreceptor in porcine seminal vesicles.Proc. Natl. Acad. Sci. USA838824–8828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Mahlmann, S., Meyerhof, W., Hausmann, H., Heierhorst, J., Schönrock, C., Zwiers, H., Lederis, K., and Richter, D. (1994). Structure, function, and phylogeny of (Arg8) vasotocin receptors from teleost fish and toad.Proc. Natl. Acad. Sci. USA911342–1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Manning, M., and Sawyer, W. H. (1993). Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin.J. Recept. Res.13195–214. [DOI] [PubMed] [Google Scholar]
  58. Manning, M., Bankowski, K., Barberis, C., Jard, S., Elands, J., and Chan, W. Y. (1992). Novel approach to the design of synthetic radioiodinated linear V1a receptor antagonists of vasopressin.Int. J. Peptide Protein Res.40261–267. [DOI] [PubMed] [Google Scholar]
  59. Marchingo, A. J., Abrahams, J. M., Woodcock, E. A., Smith, A. I., Mendelsohn, F. A. O., and Johnston, C. I. (1988). Properties of [3H] 1-Desamino-8-D-Arginine vasopressin as a radioligand for vasopressin V2-receptor in rat kidney.Endocrinology1221328–1336. [DOI] [PubMed] [Google Scholar]
  60. Meck, W. J. (1987). Vasopressin metabolite neuropeptide facilitates simultaneous temporal processing.Behav. Brain Res.23147. [DOI] [PubMed] [Google Scholar]
  61. Melin, P. (1993). Oxytocin antagonists and their their therapeutic use.Reg. Peptides45285–288. [DOI] [PubMed] [Google Scholar]
  62. Morel, A., O'Carroll, A.-M., Brownstein, M. J., and Lolait, S. J. (1992). Molecular cloning and expression of a Rat V1a arginine vasopressin receptor.Nature356523–526. [DOI] [PubMed] [Google Scholar]
  63. Mouillac, B., Chini, B., Balestre, M. N., Elands, J., Trumpp-Kallmeyer, S., Hoflack, J., Hibert, M., Jard, S., and Barberis, C. Identification of agonist binding site of V1a vasopressin receptors (submitted). [PubMed]
  64. Ohnishi, A., Orita, Y., Takagi, N., Fujita, T., Toyoki, T., Ihara, Y., Yamamura, Y., Inoue, T., and Tanaka, T. (1995). Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men.J. Pharmacol. Exp. Ther.272546–551. [PubMed] [Google Scholar]
  65. Ostrowski, N. L., Lolait, S. J., Bradley, D. J., O'Carroll, A. M., Brownstein, M. J., and Scott Young, W. (1992). Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain.Endocrinology131533–535. [DOI] [PubMed] [Google Scholar]
  66. Pettibone, D. J., Clineschmidt, B. V., Anderson, P. S., Freidinger, R. M., Lundell, G. F., Koupal, L. R., Schwartz, C. D., Williamson, J. M., Goetz, M. A., Hensens, O. D., Liesch, J. M., and Springer, J. P. (1989). A structurally unique, potent and selective oxytocin antagonist derived from Streptomyces silvensis.Endocrinology125217–222. [DOI] [PubMed] [Google Scholar]
  67. Pettibone, D. J., Kishel, M. T., Woyden, C. J., Clineschmidt, B. V., Bock, M. G., Freidinger, R. M., Veber, D. F., and Williams, P. D. (1992). Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues.Life Sci.501953–1958. [DOI] [PubMed] [Google Scholar]
  68. Rajerison, R., Marchetti, J., Roy, C., Bockaert, J., and Jard, S. (1974). The vasopressin-sensitive adenylyate cyclase of the rat kidney: Effects of adrenalectomy and corticosteroids on hormonal receptor-enzyme coupling.J. Biol. Chem.2496390–6400. [PubMed] [Google Scholar]
  69. Rivier, C., Rivier, J., Mormede, P., and Vale, W. (1984). Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.Endocrinology115882–886. [DOI] [PubMed] [Google Scholar]
  70. Rong, X. W., Chen, X. F., and Du, Y. C. (1993). Potentiation of synaptic transmission by neuropeptide AVP4–8 (ZNC(C)PR) in rat hippocampal slices.Neuroreport41135–1138. [PubMed] [Google Scholar]
  71. Rosenkilde, M. M., Cahir, M., Gether, U., Hjorth, S. A., and Schwartz, T. W. (1994). Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding.J. Biol. Chem.26928160–28164. [PubMed] [Google Scholar]
  72. Roy, C., Barth, T., and Jard, S. (1975). Vasopressin-sensitive kidney adenylate cyclase: Structural requirement for attachment to the receptor and enzyme activation. I. Studies with vasopressin analogues.J. Biol. Chem.2503149–3156. [PubMed] [Google Scholar]
  73. Rozen, F., Russo, C., Banville, D., and Zingg, H. H. (1995). Structure, characterization, and expression of the rat oxytocin receptor gene.Proc. Natl. Acad. Sci. USA92200–204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Schlosser, S. F., Almeida, O. F. X., Patchev, V. K., Yassouridis, A., and Elands, J. (1994). Oxytocin-stimulated release of adrenocorticotropin from the rat pituitary is mediated by arginine vasopressin receptors of the V1b type.Endocrinology1352058–2063. [DOI] [PubMed] [Google Scholar]
  75. Schmidt, A., Audigier, S., Barberis, C., Jard, S., Manning, M., Kolodziejczyk, A. S., and Sawyer, W. H. (1991). A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors.FEBS Lett.28277–81. [DOI] [PubMed] [Google Scholar]
  76. Schwartz, T. W. (1994). Locating ligand-binding sites in 7TM receptors by protein engineering.Curr. Opinion Biotechnol.5434–444. [DOI] [PubMed] [Google Scholar]
  77. Schwartz, J., Derdowska, I., Sobocinska, M., and Kupryszewski, G. (1991). A potent new synthetic analog of vasopressin with relative agonist specificity for the pituitary.Endocrinology1291107–1109. [DOI] [PubMed] [Google Scholar]
  78. Serradeil-Le Gal, C., Wagnon, J., Garcia, C., Lacour, P., Guiradou, P., Christophe, B., Villanova, G., Nisato, D., Maffrand, J. P., Le Fur, G., Guillon, G., Cantau, B., Barberis, C., Trueba, M., Ala, Y., and Jard, S. (1993). Biochemical and pharmacological properties of SR 49059, a new potent, non-peptide antagonist of rat and human vasopressin V1a receptors.J. Clin. Invest.92224–231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Serrdeil-Le Gal, C., Raufaste, D., Marty, E., Garcia, C., Maffrand, J. P., and Le Fur, G. (1994). Binding of [3H] SR 49059, a potent non peptide vasopressin V1a antagonist, to rat and human liver membranes.Biochem. Biophys. Res. Commun.199353–360. [DOI] [PubMed] [Google Scholar]
  80. Soloff, M. S., and Swartz, T. L. (1973). Characterization of a proposed oxytocin receptor in the uterus of the rat and sow.J. Biol. Chem.2486471–6478. [PubMed] [Google Scholar]
  81. Stassen, F. L., Heckman, G., Schmidt, D., Stefankiewicz, J., Sulat, L., Huffman, W. F., Moore, M. M., and Kinter, L. B. (1995). Actions of vasopressin antagonists: Molecular mechanisms. In Schrier, R. W. (ed.),Vasopressin, Raven Press, New York, pp. 145–154. [Google Scholar]
  82. Stassen, F. L., Heckman, G., Schmidt, D., Nambi, P., Aiyar, N., Landvatter, S., and Crooke, T. (1987). A novel radiolabeled vasopressin antagonist: [3H-Phe]-desGly d(CH2)5D-Tyr(Et)VVP, [3H]-SK&F 1101926.Mol. Pharmacol.31267–272. [PubMed] [Google Scholar]
  83. Sugimoto, T., Saito, M., Mochizuki, S., Watanabe, Y., Hashimoto, S., and Kawashima, H. (1994a). Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.J. Biol. Chem.26927088–27092. [PubMed] [Google Scholar]
  84. Sugimoto, T., Saito, M., Shinobu, S., Watanabe, Y., Hashimoto, S., and Kawashima, H. J. (1994b). Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.J. Biol. Chem.26927088–27092. [PubMed] [Google Scholar]
  85. Thibonnier, M., Bayer, A. L., Simonson, M. S., and Kester, M. (1991). Multiple signaling pathways of V1-vascular vasopressin receptors of A7r5 cells.Endocrinology1292845–2855. [DOI] [PubMed] [Google Scholar]
  86. Thibonnier, M., Auzan, C., Madhun, Z., Wilkins, P., Berti-Mattera, L., and Clauser, E. (1994). Molecular cloning, sequencing and functional expression of a cDNA endocing the human V1a vasopressin receptor.J. Biol. Chem.2693304–3310. [PubMed] [Google Scholar]
  87. Tribollet, E. (1992). Vasopressin and oxytocin receptors in the rat brain. In Björklund, T., Hökfelt, T., and Kuhar, M. J. (eds.),Handbook of Chemical Neuroanatomy (Vol. 4), Elsevier, Amsterdam, pp. 289–320. [Google Scholar]
  88. Tribollet, E., Barberis, C., Jard, S., Dubois-Dauphin, M., and Dreifuss, J. J. (1988). Localization and pharmacological characterization of high affinity binding sites for vasopressin and oxytocin in the rat brain by light microscopic autoradiography.Brain Res.42105–118. [DOI] [PubMed] [Google Scholar]
  89. Trinder, D., Stephenson, J. M., Gao, X., Phillips, P. A., Risvanis, J., and Johnston, C. I. (1991). [3H] des Gly-NH29-d(CH2)5 [D-Ileu2, Ileu4] VP: An VP V2 receptor antagonist radioligand.Peptides121195–1200. [DOI] [PubMed] [Google Scholar]
  90. De Wied, D., Elands, J., and Kovács, G. (1991). Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behaviour: Mediation by a cerebral neurohypophyseal hormone receptor?Proc. Natl. Acad. Sci.881494–1498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. De Wied, D., Diamant, M., and Fodor, M. (1993). Central nervous system effects of the neurohypophyseal hormones and related peptides.Front. Neuroendocrinol.14251–302. [DOI] [PubMed] [Google Scholar]
  92. Williams, P. D., Anderson, P. S., Ball, R. G., Bock, M. G., Carroll, L. A., Chiu, S. H. L., Clineschmidt, B. V., Culberson, J. C., Erb, J. M., Evans, B. E., Fitzpatrick, S. L., Freidinger, R. M., Kaufman, M. J., Lundell, G. F., Murphy, J. S., Pawluczyk, J. M., Perlow, D. E., Pettibone, D. J., Pitzenberger, S. M., Thompson, K. L., and Veber, D. F. (1994). 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4- (methylsulfonyl) butyramido) bicyclo[2.2.1]-heptan- 1(S)-yl)methsulfonyl)-4-(2-methylphenyl) piperazine (L-368, 899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.J. Med. Chem.37565–571. [DOI] [PubMed] [Google Scholar]
  93. Yamamura, Y., Ogawa, H., Chihara, T., Kondo, K., Onogawa, T., Nakamura, S., Mori, T., Tominaga, M., and Yabuuchi, Y. (1991). OPC-21268, an orally effective, non-peptide vasopressin V1 receptor antagonist.Science252572–574. [DOI] [PubMed] [Google Scholar]
  94. Yamamura, Y., Ogawa, H., Kondo, K., Yamashita, H., Chihara, T., Nakamura, S., Onogawa, T., Yamashita, T., Yamada, Y., Tsujimae, K., Mori, T., Tominaga, M., and Yabuuchi, Y. (1993). Development and pharmacology of non-peptide V1 and V2 vasopressin receptor antagonists. In Gross, P., Richter, D., and Robertson, G. L. (eds.)Vasopressin, John Libbey Eurotext, Paris, pp. 507–515. [Google Scholar]
  95. Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Onogawa, T., Yamashita, T., Hosokawa, T., Mori, T., Tominaga, M., and Yabuuchi, Y. (1992). Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, non-peptide vasopressin V2 receptor antagonist.Br. J. Pharmacol.105787–791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Zachary, I., Sinnett-Smith, J., Turner, Ch. E., and Rozengurt, E. (1993a). Bombesin, vasopressin, and endothelin rapidly stimulate tyrosine phosphorylation of the focal adhesion-associated protein paxillin in Swiss 3T3 cells.J. Biol. Chem.26822060–22065. [PubMed] [Google Scholar]
  97. Zachary, I., Sinnett-Smith, J., and Rozengurt, E. (1993b). Bombesin, vasopressin, and endothelin stimulation of tyrosine phosphorylation in Swiss 3T3 cells.J. Biol. Chem.26719031–19034. [PubMed] [Google Scholar]

Articles from Cellular and Molecular Neurobiology are provided here courtesy of Springer

RESOURCES